Vignesh Pharma Marketing Profile
Key Indicators
- Authorised Capital ₹ 1.60 M
as on 03-07-2024
- Paid Up Capital ₹ 0.80 M
as on 03-07-2024
- Company Age 15 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Revenue -84.53%
(FY 2020)
- Profit -439.97%
(FY 2020)
- Ebitda -99.92%
(FY 2020)
- Net Worth -33.93%
(FY 2020)
- Total Assets -29.74%
(FY 2020)
About Vignesh Pharma Marketing
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.60 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Meena Dudani, Mahesh Dudani, Hassan Jayashree, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51397KA2009PTC051624
- Company No.
051624
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vignesh Pharma Marketing?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meena Dudani  | Director | 25-Feb-2011 | Current |
| Mahesh Dudani | Director | 25-Nov-2009 | Current |
| Hassan Jayashree | Director | 25-Nov-2009 | Current |
| Manjunath Ramachandra | Director | 25-Nov-2009 | Current |
| Hassan Nataraja | Director | 25-Nov-2009 | Current |
| Shailaja Manjunath | Director | 11-Jul-2011 | Current |
Financial Performance of Vignesh Pharma Marketing.
Vignesh Pharma Marketing Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 84.53% decrease. The company also saw a substantial fall in profitability, with a 439.97% decrease in profit. The company's net worth observed a substantial decline by a decrease of 33.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vignesh Pharma Marketing?
In 2019, Vignesh Pharma Marketing had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vignesh Pharma Marketing?
Vignesh Pharma Marketing has a workforce of 2 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vignesh Pharma Marketing, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vignesh Pharma Marketing's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
